The QWINT-1 study evaluated weekly efsitora versus daily glargine U100 in insulin-naïve adults with type 2 diabetes (n=397 and 398, respectively), with a focus on patient-reported outcomes. EASD 2025 highlighted findings from TRIM-D, DTSQc, SIM-Q, and BIE instruments assessing treatment burden, daily life impact, treatment satisfaction, complexity, and likelihood of long-term use.

At week 52, participants in both groups experienced improvements across all TRIM-D domains, but reductions in treatment burden were significantly greater with efsitora. DTSQc scores indicated modest but significant increases in treatment satisfaction with efsitora compared to glargine (15.1 vs 14.5; p=0.029). On the SIM-Q, similar proportions rated weekly insulin as “very simple” (54% efsitora vs 49% glargine). Importantly, BIE results showed that a higher proportion of participants were “very likely” to adopt efsitora into their routine (63% vs 50%; p=0.005).

These findings suggest weekly efsitora not only improves health outcomes but also reduces the perceived burden of insulin therapy, potentially enhancing adherence and long-term diabetes management in insulin-naïve adults.